Navigation Links
Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
Date:12/18/2007

ment Board. "We believe we are on track to provide initial results from this clinical trial during the first quarter of 2008."

About Acute Migraine Headaches

According to the National Headache Foundation, approximately 13 million people in the United States have been diagnosed with migraine headaches. Acute migraine headaches occur often, usually one to four times a month. Of the estimated 29.5 million migraine sufferers (including diagnosed and undiagnosed sufferers), there are at least two groups of potential patients for whom we believe AZ-001 and AZ-104 could be effective and safe in comparison to triptans. Many migraine sufferers who do take triptans have an insufficient therapeutic response to these medications. In addition, according to the warning labels on triptans, patients with hypertension or high cholesterol, or who smoke cigarettes, are contraindicated for and should not take these medications due to potential cardiovascular health risks.

About AZ-104 (Staccato loxapine)

AZ-104 is the combination of Alexza's proprietary Staccato system with loxapine, a drug belonging to the class of compounds known as antipsychotics. In a Phase 1 dose-escalation clinical trial, doses of Staccato loxapine ranging from 0.625 to 10 mg were generally well tolerated and there were no serious adverse events. Across all doses, pharmacokinetic analyses revealed that peak plasma levels were generally reached within the first few minutes after dosing and the drug exhibited good dose proportionality. Alexza and Symphony Allegro are also developing Staccato loxapine (AZ-004) for the treatment of acute agitation in patients with schizophrenia or bipolar disorder. In March 2007, Alexza announced positive initial results from a Phase 2a clinical trial where a 10 mg dose of AZ-004 was statistically significantly effective, compared to placebo, in reducing agitation in schizophrenic patients following self-administration of the drug during an in-clinic study
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)...  Instrumentation Laboratory (IL) today announced the launch of its ... is part of a comprehensive rebranding effort by Werfen, the ... Boston, MA , in 1959, IL has been part ... companies in the group include Inova Diagnostics ( San ... Spain ).  Like IL, these three companies are focused ...
(Date:7/29/2014)... Research and Markets has announced the addition ... report to their offering. ... medical device used to provide medication or assist a ... achieve adequate oxygen levels to maintain life. Patients with ... ARDS require the need of respiratory devices. The medication ...
(Date:7/29/2014)... , July 29, 2014  Based on its ... (PERS) market, Frost & Sullivan recognizes MobileHelp with ... for Price Performance Value Leadership. MobileHelp,s leadership in ... expectations for tech progression in personal emergency response, ... these solutions. MobileHelp is at the ...
Breaking Medicine Technology:Instrumentation Laboratory Unveils New Corporate Brand 2Instrumentation Laboratory Unveils New Corporate Brand 3Global Respiratory Devices Market 2014-2018 2Frost & Sullivan Applauds MobileHelp for its Targeted Supplies for the PERS Market 2Frost & Sullivan Applauds MobileHelp for its Targeted Supplies for the PERS Market 3
... Horizon Pharma, Inc. announced today that it has filed a registration statement ... a proposed initial public offering of shares of its common stock.  All shares ... by the Company. , , , ... & Company, Inc. and Piper Jaffray & Co. are acting as ...
... Pharmaceuticals (NYSE: WPI ) today announced that ... as Senior Vice President, Global Operations, has been promoted to Executive Vice ... Bisaro , President and Chief Executive Officer of Watson. , ... Mr. Stewart will assume responsibility ...
Cached Medicine Technology:Horizon Pharma, Inc. Files Registration Statement for Proposed Initial Public Offering 2Watson Promotes Robert Stewart to Executive Vice President, Global Operations 2Watson Promotes Robert Stewart to Executive Vice President, Global Operations 3
(Date:7/29/2014)... 2014 DailyGossip.org reveals in its latest review ... who can perfectly understand patients and what they have to ... Gadsby is the author of the new program. Ellie claims ... of suffering, Ellie started her very own research. Four years ... The author of the Get Rid of Cold Sores program ...
(Date:7/29/2014)... Daily Gossip indicates in its Natural ... created by a popular nutritionist and health specialist. Michael ... for this disorder, but none of them worked. , ... of having to look for an alternative vitiligo treatment, ... this method, too, to become vitiligo free. , ...
(Date:7/29/2014)... 2014 For survivors of severe combat injuries threatening ... flaps have a good record of safety and effectiveness ... issue of Plastic and Reconstructive Surgery ... Society of Plastic Surgeons (ASPS). , Experience with ... and Afghanistan shows good success rates, with no increase ...
(Date:7/29/2014)... 29, 2014 (HealthDay News) -- Although the bite of ... heal well if left alone, an expert notes. ... an adverse reaction to a brown recluse spider bite, ... Poison Center, particularly since these potentially dangerous bites are ... for us to do nothing. The [bite] has classic ...
(Date:7/29/2014)... NH (July 29, 2014) Using quality improvement measures ... New England Cardiovascular Disease Study Group, researchers have found ... a procedure with contrast dye. , Currently, 7-15 percent ... with contrast-dye end up with kidney injury, which can ... leading to temporary or permanent dialysis, says a study ...
Breaking Medicine News(10 mins):Health News:Get Rid of Cold Sores Fast Review Exposes the Way to Stop Outbreaks 2Health News:Natural Vitiligo Treatment System Review Reveals Michael Dawson’s New Vitiligo Cure Program 2Health News:Good outcomes with multiple limb salvage after severe combat injuries, reports Plastic and Reconstructive Surgery 2Health News:Brown Recluse Spider Bites on the Rise, Expert Warns 2Health News:Reducing kidney injury using a quality improvement method 2
... Doctor, Health officials of the NHS Grampian said that people ... // The NHS health board said so defending their decision ... wards. ,A spokeswoman for NHS Grampian said a ... be suitable for a patient to stay outwith the city's ...
... is a fungal infection affecting mostly children in North America. ... affected by ringworm infections. //It is a highly contagious skin ... symptoms such as scaly scalp and hair loss which can ... household pets but in rare occasions it is passed easily ...
... The authorities in Delhi have blamed the poor quality of ... the last four months. So far 222 cases have been ... against 92 in the corresponding period last year. But we ... well under control," said N.K. Yadav, deputy municipal health officer ...
... Zealand have warned against using traditional Indian medicines after ... reported Friday.// ,"We wish to alert the medical ... a particular form of herbal remedy, namely, Ayurvedic medicine," ... Zealand Medical Journal. ,The eight patients suffered ...
... Delhi High Court has demanded an explanation from the medical ... boy suffering from cancer got inflicted with AIDS after undergoing ... an explanation on why the relevant documents were not being ... Sen ruled that the blood transfusion was the business of ...
... In the event of an influenza pandemic set into action by ... are we to handle// a mega crisis, and what plan of ... the responses to an epidemic, eight Asia Pacific countries are teaming ... gauge the effectiveness of a global response to a pandemic. ...
Cached Medicine News:
ELISA for detection of Anti-Gliadin IgA....
An enzyme-linked immuno-sorbent assay for the detection and quantitation of anti-tissue Transglutaminase in serum of patients with Celiac Disease and Dermatitis Herpetiformis....
Enzyme immunoassay for the quantitative determination of Gliadin-IgA antibodies in serum and plasma. This kit provides specific determination of gliadin antibodies by using highly purified gliadin....
... immunosorbent assay method for the semi-quantitative determination ... human serum. The results of the anti-Gliadin ... aid in the diagnosis of diseases associated ... Coeliac Disease. Levels of these autoantibodies are ...
Medicine Products: